http://yerbabuenainstitut e.org/gft505-shows-a-potent ial-atherogenic-in-dyspli dipemia/
December 3, 2012 admin healthcare
Results of the Phase IIa study showed that the GFT505 produced a significant reduction of 21 percent triglycerides and a significant increase of 9 percent in high-density lipoprotein -cholesterol.GFT505 was well tolerated and no patient had to leave the study early because of side effects.
These improvements in lipid profile with GFT505 treatment were comparable to those reported with fibrates, which are commonly used in this population, said Staels.
These are patients with atherogenic dyslipidemia and elevated levels of HDL cholesterol and triglycerides, which were launched with statins, which we believe could potentially benefit from GFT 505, he added.
GFT505 survey is a dual PPAR / agonist being tested for the management of metabolic disorders, including atherogenic dyslipidemia associated with metabolic syndrome and type II.
The active agent was also associated with a decrease in pro-atherogenic apolipoprotein ApoCIII and ApoB and increasing anti-atherogenic and ApoA1 apolilipoteins ApoAIII.
ORLANDO – GFT505 appears to be safe and effective for the treatment of atherogenic dyslipidemia and pre-diabetes , according to data from two Phase IIa studies reported here in the 70 Annual Scientific Sessions of the American Diabetes Association .
In addition, the agent improved two markers of dysfunction of the goose liver, while the plasma levels of aspartate aminotransferase was unchanged.
In a phase IIa study in patients with the second fasting glucose and impaired glucose tolerance, GFT505 treatment reduced fasting glucose and insulin concentrations and improved HOMA-IR, suggesting improved insulin sensitivity.
This test also confirmed the beneficial effects of GFT505 on plasma lipids, apolipoproteins and markers of inflammation.
